skip to main content

IRON DEFICIENCY AND GENETIC REGULATION IN TUBERCULOSIS THROUGH MOLECULAR HOST-PATHOGEN INTERACTIONS

*Grace Puspasari orcid  -  Department of Biochemistry, Universitas Kristen Maranatha, Jl. Surya Sumantri, Bandung, Indonesia,40164, Indonesia
Open Access Copyright 2025 Grace Puspasari
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Citation Format:
Abstract

Background: Anemia is a frequent comorbidity in tuberculosis (TB), often driven by chronic inflammation and dysregulated iron metabolism. Elevated hepcidin levels limit iron availability by suppressing ferroportin, leading to functional iron deficiency and impaired erythropoiesis. Objective: This review discusses the molecular mechanisms linking iron metabolism, host immune response, and Mycobacterium tuberculosis persistence, particularly in the context of drug-resistant TB. Content:  We summarize current knowledge on the hepcidin–ferroportin axis, siderophore-mediated iron acquisition by M. tuberculosis, and the diagnostic value of biomarkers such as ferritin, transferrin saturation, and soluble transferrin receptor. Considerations for iron therapy, including its risks during active inflammation and emerging targeted treatments, are also addressed. Conclusion: Anemia in TB requires a selective, biomarker-guided approach. While iron supplementation may benefit those with true deficiency, improper use can worsen infection. Targeted modulation of iron pathways offers promising therapeutic alternatives.

Fulltext View|Download
Keywords: Tuberculosis,;Anemia; Iron metabolism; Hepcidin; Iron therapy

Article Metrics:

  1. Indonesia PDP. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. 2nd ed. Jakarta: Perhimpunan Dokter Paru Indonesia; 2021. 81 p
  2. Dasaradhan T, Koneti J, Kalluru R, Gadde S, Cherukuri SP, Chikatimalla R. Tuberculosis-Associated Anemia: A Narrative Review. Cureus. 2022;14(8):e27746
  3. Nienaber A, Uyoga MA, Dolman-Macleod RC, Malan L. Iron Status and Supplementation during Tuberculosis. Microorganisms. 2023;11(3)
  4. Ali A, Wu L, Moazen EM, Elsawy SB, Salama KSM, Ullah K, et al. Hematological profiles and mortality risk in critically ill and drug-resistant tuberculosis patients: insights from a longitudinal study. The Egyptian Journal of Bronchology. 2024;18(1):40
  5. Beshaw MA, Siraj EM, Demass TB, Lakew AM. Severity and associated factors of anaemia among rifampicin/multi-drug-resistant tuberculosis patients treated in Alert and St. Peters specialised hospitals, Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMJ Open. 2025;15(5):e091111
  6. Cercamondi CI, Stoffel NU, Moretti D, Zoller T, Swinkels DW, Zeder C, et al. Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis. Blood. 2021;138(15):1293-303
  7. Sritharan M. Iron Homeostasis in Mycobacterium tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake. J Bacteriol. 2016;198(18):2399-409
  8. Pandey M, Talwar S, Bose S, Pandey A. Iron homeostasis in Mycobacterium tuberculosis is essential for persistence. Scientific Reports. 2018;8
  9. Rodriguez GM, Sharma N, Biswas A. The Iron Response of Mycobacterium tuberculosis and Its Implications for Tuberculosis Pathogenesis and Novel Therapeutics. Front Cell Infect Microbiol. 2022;12:876667
  10. Wessling-Resnick M. Iron. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, editors. Modern Nutrition in Health and Disease. 11 ed: Wolters Kluwer/ Lippincolt William & Wilkins; 2014
  11. Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106(Suppl 6):1559s-66s
  12. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260-72
  13. Liu J, Sun B, Yin H, Liu S. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Medicine (Baltimore). 2016;95(14):e3150
  14. Gokhale KM, Iyer AM. Deployment of iron uptake machineries as targets against drug resistant strains of mycobacterium tuberculosis. Indian J Pharmacol. 2022;54(5):353-63
  15. Leon J, Sarkar S, Basu D, Nanda N, Joseph NM. Anaemia of chronic disease among pulmonary tuberculosis patients is associated with inflammatory marker at the start of intensive phase. J Family Med Prim Care. 2024;13(4):1316-27
  16. Vyas S, Suman S, Kapoor A, Nema SK. Evaluation of serum hepcidin as a biochemical marker in diagnosis of anemia of chronic disease. International Journal of Research in Medical Sciences. 2018;6(6):1971-6
  17. Laller S, Patel S, Haldar D. Role of Serum and Urinary Hepcidin in Young Females of Reproductive Age in North India. J Lab Physicians. 2022;14(2):175-82
  18. Tarancon-Diez L, Genebat M, Roman-Enry M, Vázquez-Alejo E, Espinar-Buitrago MD, Leal M, et al. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency. Nutrients [Internet]. 2022; 14(22)
  19. Irbah SN, Pratiwi AP, Vidiast F, Handayani D. The impact of anemia in prolong culture conversion amongs MDR-TB patients in persahabatan hospital Indonesia. International Journal of Infectious Diseases. 2019;79:91
  20. Kumar RNH, Rao CR, Maradi R, Umakanth S, Sanju SVC, Rao BPS. Impact of Anemia on Sputum Smear Conversion and Treatment Outcomes among Newly Diagnosed Tuberculosis Patients in Southern India. The International Journal of Mycobacteriology. 2023;12(2)
  21. Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Molecular Aspects of Medicine. 2020;75:100862
  22. Nicole US, Christophe Z, Gary MB, Diego M, Michael BZ. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105(5):1232-9

Last update:

No citation recorded.

Last update:

No citation recorded.